MRI contrast developer Epix Pharmaceuticals reported sales of $2.3 million for the company's fiscal 2005 third quarter (end-September 30), a drop compared with revenues of $3.2 million reported for the same period in fiscal 2004.
The Cambridge, MA, company's net loss, in comparison with the third quarter of fiscal 2004, shrunk during the quarter to $5.7 million, compared with a net loss of $6.4 million in the corresponding period of 2004.
By AuntMinnie.com staff writers
November 1, 2005
Related Reading
Schering, Epix score European approval for Vasovist, October 5, 2005
Webb steps down at Epix, September 15, 2005
Epix sales fall, net loss grows, July 28, 2005
Epix makes management moves, July 6, 2005
Epix's Vasovist moves closer to market, July 1, 2005
Copyright © 2005 AuntMinnie.com
